Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
1
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
16
Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung ...
Jan 30, 2021
0
2
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).
May 4, 2017
0
0
(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab versus sunitinib have longer treatment-free survival (TFS), according to a study published online ...
Dec 3, 2021
0
9
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...
May 10, 2023
0
40
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers ...
Mar 29, 2017
0
18
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ...
Oct 22, 2018
0
5
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small ...
Oct 22, 2023
0
33
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small ...
May 15, 2024
0
52
